Literature DB >> 8305617

Apolipoprotein E to B ratio: a marker for type III hyperlipoproteinaemia.

W März1, G Feussner, R Siekmeier, B Donnerhak, L Schaaf, V Ruzicka, W Gross.   

Abstract

Apolipoproteins B and E were determined in 40 patients with type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia) and in 48 patients with other types of hyperlipoproteinaemia matched for cholesterol and triacylglycerols. In type III patients, apolipoprotein E was increased and apolipoprotein B was lower than in other types of hyperlipoproteinaemia. The apolipoprotein E to apolipoprotein B ratio almost completely discriminated between type III and other types of hyperlipoproteinaemia. Assuming a cut-off value of 0.09 for the apolipoprotein E to apolipoprotein B ratio, diagnostic sensitivity was 95% and specificity was 88%. It is concluded that the apolipoprotein E to apolipoprotein B ratio represents the first-line screening quantity of choice for the identification of patients with type III hyperlipoproteinaemia in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305617     DOI: 10.1515/cclm.1993.31.11.743

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  2 in total

1.  Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.

Authors:  Paul N Hopkins; M Nazeem Nanjee; Lily L Wu; Michael G McGinty; Eliot A Brinton; Steven C Hunt; Jeffrey L Anderson
Journal:  Atherosclerosis       Date:  2009-05-22       Impact factor: 5.162

2.  Apolipoprotein E gene polymorphism and renal function are associated with apolipoprotein E concentration in patients with chronic kidney disease.

Authors:  Monika Czaplińska; Agnieszka Ćwiklińska; Monika Sakowicz-Burkiewicz; Ewa Wieczorek; Agnieszka Kuchta; Robert Kowalski; Barbara Kortas-Stempak; Alicja Dębska-Ślizień; Maciej Jankowski; Ewa Król
Journal:  Lipids Health Dis       Date:  2019-03-09       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.